Antibiotic exposure and IBD development among children: A population-based cohort study

Pediatrics

Volumn 130, Issue 4, 2012, Pages

  Kronman, Matthew P ^a   Zaoutis, Theoklis E ^b,c   Haynes, Kevin ^c   Feng, Rui ^c   Coffin, Susan E ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antimicrobials; Epidemiology; Inflammatory bowel disease; Pediatric; Population based studies

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOXITIN; CLINDAMYCIN; LINCOSAMIDE; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; VANCOMYCIN;

ADOLESCENT; AGE; ARTICLE; CHILD; CHILDHOOD; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; ENTERITIS; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATIENT SELECTION; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; UNITED KINGDOM;

EID: 84867173210     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3886     Document Type: Article

References (34)

1. Barrett JC, Hansoul S, Nicolae DL, et al NIDDK IBD Genetics Consortium; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40(8):955-962
2. Tysk C, Lindberg E, Järnerot G, Flodérus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 1988;29(7):990-996
3. Malaty HM, Fan X, Opekun AR, Thibodeaux C, Ferry GD. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr. 2010;50(1):27-31
4. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577-594 (Pubitemid 351173057)
5. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137(2):495-501
6. Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7(9):607-613 (Pubitemid 47268226)
7. Jess T, Simonsen J, Nielsen NM, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut. 2011;60(3):318-324
8. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53(5):685-693 (Pubitemid 38561447)
9. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131(1):33-45 (Pubitemid 47505255)
10. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatorycommensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105(43):16731-16736
11. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280
12. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol. 1987;22(8):1009-1024 (Pubitemid 17152843)
13. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci. 1994;39(3):555-560 (Pubitemid 24137343)
14. Han DY, Fraser AG, Dryland P, Ferguson LR. Environmental factors in the development of chronic infl ammation: a case-control study on risk factors for Crohn's disease within New Zealand. Mutat Res. 2010;690 (1-2):116-122
15. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25(2):325-333
16. Ruemmele FM, El Khoury MG, Talbotec C, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. J Pediatr Gastroenterol Nutr. 2006;43(5):603-609 (Pubitemid 44863685)
17. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol. 2008;43(8):961-966
18. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2687-2692
19. Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease - a nationwide, register-based Finnish case-control study. Am J Epidemiol. 2012;175(8):775-784
20. Card T, Logan RF, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn's disease. Gut. 2004;53(2):246-250 (Pubitemid 38125513)
21. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133-2142
22. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610-2616
23. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54
24. CSD Medical Research UK. THIN data statistics. Available at: http://csdmruk.cege-dim.com/. Accessed December 15, 2011
25. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2005;14(7):443-451 (Pubitemid 40990739)
26. Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2002;11(3):211-218 (Pubitemid 34537527)
27. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393-401 (Pubitemid 46656860)
28. Hersh AL, Shapiro DJ, Pavia AT, Shah SS. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011;128(6):1053-1061
29. Lowe AM, Roy PO, B-Poulin M, et al. Epidemiology of Crohn's disease in Québec, Canada. Inflamm Bowel Dis. 2009;15(3):429-435
30. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911-920
31. Lichtenstein DR. Hepatobiliary Complications of in fl ammatory bowel disease. Curr Gastroenterol Rep. 2011;13(5):495-505
32. Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol. 2009;104(1):117-124
33. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA. 2002;287(23):3096-3102 (Pubitemid 34633984)
34. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302(7):758-766